Cyclin-Dependent Kinase 4
"Cyclin-Dependent Kinase 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Cyclin-dependent kinase 4 is a key regulator of G1 PHASE of the CELL CYCLE. It partners with CYCLIN D to phosphorylate RETINOBLASTOMA PROTEIN. CDK4 activity is inhibited by CYCLIN-DEPENDENT KINASE INHIBITOR P16.
| Descriptor ID |
D051358
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.646.500.875 D12.644.360.250.451 D12.776.167.200.451 D12.776.476.250.451
|
| Concept/Terms |
Cyclin-Dependent Kinase 4- Cyclin-Dependent Kinase 4
- Cyclin Dependent Kinase 4
- Cdk4 Cyclin-Dependent Kinase
- Cdk4 Cyclin Dependent Kinase
- Cyclin-Dependent Kinase, Cdk4
- Cdk4 Protein
- Cdk4 Protein Kinase
- Protein Kinase, Cdk4
- p34PSK-J3 Kinase
- p34PSK J3 Kinase
- Cell Division Protein Kinase 4
- PSK-J3 Kinase
- PSK J3 Kinase
- Cyclin D-Dependent Kinase CDK4
- Cyclin D Dependent Kinase CDK4
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase 4".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase 4".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase 4" by people in this website by year, and whether "Cyclin-Dependent Kinase 4" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 2 | 2 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 2 | 1 | 3 |
| 2012 | 1 | 1 | 2 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 1 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase 4" by people in Profiles.
-
Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss. Oncogene. 2022 04; 41(15):2187-2195.
-
MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol. 2021 Mar; 23(3):612-619.
-
Evaluating anti-tumor activity of palbociclib plus radiation in anaplastic and radiation-induced meningiomas: pre-clinical investigations. Clin Transl Oncol. 2020 Nov; 22(11):2017-2025.
-
Cyclin D-CDK4/6 functions in cancer. Adv Cancer Res. 2020; 148:147-169.
-
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Sci Adv. 2019 09; 5(9):eaax6352.
-
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nat Commun. 2019 03 21; 10(1):1296.
-
Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. Curr Opin Pharmacol. 2018 08; 41:59-65.
-
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature. 2017 06 15; 546(7658):426-430.
-
Breast cancer: updates and advances in 2016. Curr Opin Obstet Gynecol. 2017 02; 29(1):12-17.
-
Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt. Mol Cell. 2016 06 16; 62(6):929-942.